Barinthus Bio Q2 net loss $10.6M; VTP-1000 trial enrollment complete; merger with Clywedog on track

Barinthus Biotherapeutics plc.

2026-Q2 EPS reported -$0.39

Net loss of $10.6M ($0.26 per share) vs $5.5M in Q1 2026; cash $59.6M as of June 30.
Completed enrollment in MAD portion of Phase 1 AVALON trial for VTP-1000 in celiac disease; topline data expected Q4 2026.
Proposed merger with Clywedog expected to close H2 2026; combined company to trade as CLYD.
Received Nasdaq extension to Dec 28, 2026 to regain bid price compliance; ADS transferred to Nasdaq Capital Market.
R&D expenses $3.9M (up from $3.6M Q1); G&A expenses $7.1M (up from $2.5M) due to FX losses and professional fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.